Trump Has Chronic Venous Insufficiency, White House Announces
White House doctors have diagnosed President Donald Trump with chronic venous insufficiency after he noticed swelling in his legs, the White House announced Thursday. White House Press Secretary Karoline Leavitt told reporters that Trump, 79, recently underwent testing to examine the swelling, which included diagnostic vascular studies and an ultrasound of his legs, revealing the vein condition. According to Johns Hopkins Medicine, chronic venous insufficiency occurs when veins in the legs struggle to allow blood to flow back up to the heart, often as a result of damaged valves in the veins. The condition affects about 1 in 20 adults. Leavitt provided the health update amid online speculation about visible swelling around Trump’s ankles and bruises on his hands, the latter of which she said was attributable to his “frequent handshaking and the use of aspirin.” She added that there was no evidence of deep vein thrombosis or arterial disease and an echocardiogram showed normal cardiac structure and function. Leavitt also said that all results from testing were “within normal limits” and that an echocardiogram showed “normal cardiac structure and function.” “The President remains in excellent health,” Leavitt said. Trump underwent his annual physical at Walter Reed National Military Medical Center in April. A report from his doctor found that the President was “in excellent health” at the time, according to the White House.Stocks making the biggest moves premarket: Cerebras, Micron, FedEx, Wendy's & more
These are the stocks posting the largest moves premarket.

GTA 6 price of $80 revealed - and 'physical' edition will not contain a disc
South Korea’s biggest chipmaker SK Hynix plans to raise $29 billion via Nasdaq listing
The company plans to issue 17.79 million new shares at a value of 45.45 trillion won ($29.65 billion).
ACNB Crosses Above Average Analyst Target
In recent trading, shares of ACNB Corp (Symbol: ACNB) have crossed above the average analyst 12-month target price of $57.33, changing hands for $58.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation,
PTGX Crosses Above Average Analyst Target
In recent trading, shares of Protagonist Therapeutics Inc (Symbol: PTGX) have crossed above the average analyst 12-month target price of $118.50, changing hands for $118.96/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: do